Endostatin - Protgen
Alternative Names: M2ES; Pegylated endostatinLatest Information Update: 02 Oct 2021
At a glance
- Originator Protgen
- Class Angiostatic proteins; Antineoplastics; Immunotherapies; Recombinant proteins
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Non-small cell lung cancer; Pancreatic cancer; Solid tumours
Most Recent Events
- 17 Aug 2015 No recent reports of development identified - Phase-I for Pancreatic cancer (Combination therapy) in China (IV)
- 17 Aug 2015 No recent reports of development identified - Phase-I for Pancreatic cancer (Second-line therapy or greater) in China (IV)
- 17 Aug 2015 No recent reports of development identified - Phase-II for Non-small cell lung cancer (Combination therapy) in China (IV)